These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s ...

LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a company that should be getting more attention from investors and the just released annual results again proved that point. LGVN ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...

Q4 2024 Earnings Call Transcript February 28, 2025 Longeveron Inc. beats earnings expectations. Reported EPS is $1.16, ...

Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Good afternoon, everyone. Welcome to the Crinetics ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...

Gorgas, President and CEO of Artelo Biosciences. “Notably, enrollment in our Phase 1 study of ART26.12, a Fatty Acid Binding Protein (FABP) inhibitor, has progressed rapidly and is expected to ...

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting ...

Q2 2025 Earnings Call Transcript February 28, 2025 Silviu Itescu: Good morning, everybody. I’m Silviu Itescu. I’m the Chief ...

LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line ...

Completed first quarter as a public company and raised $10.6 mil CAD concurrent with listing– Next-generation Novasight design freeze completed ...